Sweating occurs in approximately 10-15% of semaglutide users, making it less common than nausea but more frequent than some other side effects
It also makes sense when you value proven long-term safety
Boehringer Ingelheim International GmbH GLP-1 Receptor Agonist industry News In July 2024, Pfizer announced its plans to advance a once-daily formulation of its oral GLP-1 receptor agonist, danuglipron
No digging, no repeated attempts, no anxiety
Clinical trials have pointed out a neuroprotective effect and an improvement of clinical outcome for some anti-diabetic treatments, translating them into new therapies against neurodegenerative conditions, such as Alzheimers disease, dementia, or Parkinsons disease (Green et al., 2019
Oprea and Mizubuti reported having no disclosures.